Cite
MLA Citation
R. Califano et al.. “Brigatinib versus crizotinib in patients with ALK inhibitor–naive advanced ALK+ NSCLC: results from the phase 3 ALTA-1L trial.” Lung cancer, vol. 139, n.d., pp. S59–S60. http://access.bl.uk/ark:/81055/vdc_100099358539.0x000041